Digestive Health Global Market Report 2023 – By Product Type (Functional Foods and Beverages, Vitamins and Dietary Supplements, Other Products), By Ingredient Type (Probiotics, Prebiotics, Digestive Enzymes, Other Ingredients), By Distribution Channel (Supermarkets/Hypermarkets, Hospital Pharmacies, Online Pharmacies, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2023-2032

Digestive enzymes refer to compounds that aid in digestion by assisting with food breakdown. These proteins accelerate the chemical processes that transform food into compounds that can be absorbed by the digestive system. The salivary glands and the cells lining the stomach, pancreas, and small intestine produce (release) them. The main types of digestive enzymes are carbohydrates, protease, lipase, and other enzyme types. Lipase is a protein produced by the pancreas, a small organ located near the stomach that aids in fat digestion. The enzymes originated from animals, fungi, microbial, and plants that are used for indigestion, chronic pancreatitis, irritable bowel syndrome, and other applications. The various distribution channel includes retail stores and online stores. The global digestive enzymes market is segmented - 1) By Enzyme Type: Carbohydrates, Protease, Lipase, Other Enzyme Types 2) By Origin: Animal, Fungi, Microbial, Plant 3) By Application: Indigestion, Chronic Pancreatitis, Irritable Bowel Syndrome, Other Applications 4) By Distribution Channel: Retail Stores, Online Stores The global digestive enzymes market size grew from $0.82 billion in 2022 to $0.89 billion in 2023 at a compound annual growth rate (CAGR) of 9.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global digestive enzymes is expected to grow from $1.32 billion in 2027 at a CAGR of 10.3%. The rising prevalence of gastrointestinal disorder among different age groups drives the growth of the digestive enzymes market. Gastrointestinal disorders include disorders in the gastrointestinal tract starting from the mouth, oesophagus, stomach, small intestine, large intestine, and anus caused due to lack of digestive enzymes. Gastrointestinal disorders require the digestive enzymes to be taken orally as a dietary supplement or as a drug. The increased rates of gastrointestinal disorders are linked to smoking, diet and genetics, sanitation, increased use of antibiotics, and the changing environmental factors due to industrialization and urbanization. According to the American Gastroenterological Association’s survey published in April 2020 on the worldwide prevalence and burden of functional gastrointestinal disorders, among 73,076 adult respondents, about 40.3% of people met the diagnostic criteria for at least 1 functional gastrointestinal disorder (FGIDs). FGID was more prevalent among women than men. A large-scale multinational study found that more than 40% of the population is having FGIDs across the globe. Therefore, the increase in the prevalence of digestive diseases contributes to the growth of the digestive enzymes market. Major players in the digestive enzymes market are Garden of Life, Biotics Research Corporation, Klaire Laboratories, Abbott Nutrition, AbbVie Inc., Allergan PLC., Johnson & Johnson Inc. Amway Corporation, Food State Inc., Matsun Nutrition, Metagenics Inc., Twinlab Corporation, Food State Inc., AST Enzymes, VEMO 99 OOD, Advanced Vital Enzymes Pvt. Ltd., Zeus Biotech Limited, Vox Nutrition Inc., Enzyme Bioscience Pvt. Ltd., Metagenics, XYMOGEN Inc., Douglas Laboratories, Thorne Research, Integrative Therapeutics LLC., Pure Encapsulations, Ortho Molecular Products Inc., Designs for Health Inc., Master Supplements Inc., and Proteozymes. The potential side effects of digestive enzyme supplements and drugs restrain the growth of the digestive enzymes market. Continuous intake of digestive enzymes increases dependency on the digestive enzymes resulting in a weaker digestive system over time. The weakened digestive system leads to digestive distress, gas, nausea, bloating, decreased stomach acid, and allergic reactions accompanied by diarrhea and vomiting. For instance, the digestive enzyme bromelain causes thinning of the blood and increases the risk of excess bleeding. The thinning of the blood is the result of the anti-platelet activity caused by the drug. Thus, the side effects caused by the excess and continuous intake of digestive enzymes negatively impact the growth of the digestive enzymes market. The companies in the digestive enzymes market are investing in developing customized digestive enzymes. These customized digestive enzymes are condition-specific enzymes to support digestion for digestive sensitive patients and may contain multiple enzymes in the same product. The companies involved in manufacturing digestive enzymes are developing customized digestive enzymes to ease the digestion of different types of food. For instance, Sabinsa, a USA-based provider of herbal extracts, cosmeceuticals, minerals, and dietary supplements, formulated DigeZyme. DigeZyme is a multi-enzyme complex comprising five different enzymes, namely, cellulase, lactase, amylase, lipase, and protease. It is widely used by people who have difficulty in digesting carbohydrates, fats, and proteins, respectively. The companies are increasingly investing in developing customized digestive enzymes. In January 2020, Nestlé, a Switzerland-based food and drink processing corporation, entered into an asset purchase agreement with Allergan, an Ireland-based pharmaceutical company that acquires, develops, and markets brand name drugs, to acquire Zenpep for an amount undisclosed. Through the acquisition, Nestle aims to expand its medical nutrition portfolio by including Zenpep products to support food ingestion, digestion, and absorption. Zenpep is a medication for people who cannot digest food properly due to the lack of digestive enzymes. North America was the largest region in the digestive enzymes market in 2022. Middle East is expected to be the largest growing region in the digestive enzymes market report during the forecast period. The regions covered in the digestive enzymes analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the digestive enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The digestive enzymes market consists of sales of amylase, maltase, and lactase. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The digestive enzymes market research report is one of a series of new reports from The Business Research Company that provides digestive enzymes market statistics, including digestive enzymes industry global market size, regional shares, competitors with a digestive enzymes market share, detailed digestive enzymes market segments, market trends and opportunities, and any further data you may need to thrive in the digestive enzymes industry. The digestive enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Functional foods are highly nutritious foods that are associated with many health benefits. The benefits include prevention of nutrition deficiencies, protection against diseases, improved cholesterol levels, lower blood pressure, and promotion of proper growth & development. The main product types are bakery & cereals, dairy products, meat, fish & eggs, soy products, fats & oils, and other product types. A dairy product is milk and any of the foods made from milk, including butter, cheese, ice cream, yogurt, and condensed and dried milk. The ingredients used for functional foods are carotenoids, dietary fibers, fatty acids, minerals, prebiotics, probiotics, vitamins, and other product types. The various applications of these food products are sports nutrition, weight management, immunity, digestive health, clinical nutrition, cardio health, and other product types. The global functional foods market is segmented - 1) By Product Type: Bakery & Cereals, Dairy Products, Meat, Fish & Eggs, Soy Products, Fats & Oils, Other Product Types 2) By Ingredients: Carotenoids, Dietary Fibers, Fatty Acids, Minerals, Prebiotics & Probiotics, Vitamins, Other Ingredients 3) By Application: Sports Nutrition, Weight Management, Immunity, Digestive Health, Clinical Nutrition, Cardio Health, Other Applications The global functional foods market size will grow from $203.64 billion in 2022 to $229.7 billion in 2023 at a compound annual growth rate (CAGR) of 12.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global functional foods is expected to grow from $354.96 billion in 2027 at a CAGR of 11.5%. The increasing number of diseases is shifting consumers' focus to healthy eating, which in turn is projected to boost the demand for functional foods. Functional food provides the human body with healthy nutrition, vitamins and minerals, and reduces the risk of diseases. According to the Centre for Disease Control and Prevention, heart disease is a leading cause of death in the USA, and about 6,47,000 Americans die from heart disease every year, which is one out of every four deaths. Therefore, the increasing number of cardiovascular and other diseases across the globe is anticipated to generate higher demand for a healthy diet, which in turn, is likely to propel the revenues of the functional foods market over the forecast period. Major players in the functional foods market are Unilever, BNL Food Group, Dean Foods, The Coca-Cola Company, Arla Foods, Abbott Laboratories, PepsiCo Inc., Kraft Foods Inc., and Nestle. The higher price of functional foods market products attributed to the inclusion of healthier or natural ingredients is limiting the growth of the functional foods market. Functional foods are sold at higher prices and hold larger profit margins than conventional foods. Functional foods are priced 30 to 500% higher than comparable conventional foods. Thus, the higher prices of functional food are to act as a major restraint for the growth of the functional foods market over the forthcoming years. Key players dealing in the functional foods market are increasingly focusing on new product developments and company expansion to meet the rising demand from consumers. For instance, in January 2022, Fonterra Co-operative Group Limited, New-Zealand-based dairy company, Tillamook Country Creamery Association (TCAA), and Three Mile Canyon Farm, introduced Pro-Optima TM, A-grade functional whey protein concentrate. Pro-Optima TM can be used in cultured products such as yogurt, to enhance the textures to deliver multi-functional benefits. In July 2021, Kerry Group, an Ireland-based food company acquired Biosearch Life for a deal of $ 150 million. Through this acquisition, Kerry Group aims to expand its product portfolio in health ingredients such as probiotics and omega 3s. Biosearch Life is a Spain-based biotechnology company. Asia-Pacific was the largest region in the functional foods market in 2022. Western Europe was the second-largest region in the functional foods market. The regions covered in the functional foods analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the functional foods market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The functional foods market consists of sales of fatty acids, carotenoids, prebiotics & probiotics, vitamins, dietary fibers, minerals, and other functional foods. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The functional foods market research report is one of a series of new reports from The Business Research Company that provides functional foods market statistics, including functional food industry global market size, regional shares, competitors with functional food share, detailed functional foods market segments, market trends and opportunities, and any further data you may need to thrive in the functional food industry. The functional foods market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Digestive health supplements refer to a nutritional supplement that aids in the breakdown of food and liquids into their chemical constituents—carbohydrates, lipids, proteins, and the like—so that the body may absorb them as nutrients and utilise them for energy, cell growth, and repair, and other functions. The main products in the digestive health supplements market are prebiotics, probiotics, enzymes, fulvic acid, and other products. Prebiotics refer to a type of carbohydrate, mostly fibers, that humans cannot digest but are digestible by their gut bacteria. The main forms include capsules, tablets, powders, liquids, and other forms. They are sold through various distribution channels such as supermarkets or hypermarkets, convenience stores, specialty stores, pharmacies, e-commerce, and other distribution channels. The global digestive health supplements market is segmented - 1) By Product: Prebiotics, Probiotics, Enzymes, Fulvic Acid, Other Product 2) By Form: Capsules, Tablets, Powders, Liquids, Other Form 3) By Distribution Channel: Supermarkets/Hypermarkets, Convenience Store, Specialty Store, Pharmacies, E-Commerce, Other Distribution Channels The global digestive health supplements market size will grow from $14.02 billion in 2022 to $15.46 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the digestive health supplements is expected to grow to $22.69 billion in 2027 at a CAGR of 10.1%. The rising prevalence of digestive diseases is expected to propel the growth of the digestive health supplement market going forward. A digestive disease is any health problem that affects the digestive tract. These problems can range from mild to severe. Digestive health supplements like probiotics, prebiotics, and enzymes help with digestive problems like diarrhea, constipation, inflammatory bowel disease, irritable bowel disease, urinary tract infection, and other gastrointestinal-related digestive problems. For instance, according to the International Foundation for Gastrointestinal Disorders, irritable bowel syndrome is the most common functional GI disorder, with a prevalence rate of 10–15% globally. Additionally, it is one of the most common conditions that require a visit to the doctor. Thus, the rising prevalence of digestive diseases will increase sales and awareness of digestive health supplements, thereby, driving the digestive health supplement market growth. Major players in the digestive health supplements market are Amway Corp, Bayer AG, Pfizer Inc., NOW Foods, Alimentary Health Limited, Nestle, Nutricia, Lonza, Nature’s Bounty, Garden of Life, Zenwise, OLLY Public Benefit Corporation, BASF SE, Herbalife International, and GlaxoSmithKline PLC. Product innovation is the key trend gaining popularity in the digestive health supplements market. Major companies operating in the market are introducing technological innovations such as new ingredients and exploring innovative administration forms to cater to the needs of various age groups to sustain their position in the market. For instance, in April 2021, Bausch Health Companies Inc., a US-based pharmaceutical company, launched a unique proprietary blend of five probiotic strains ingredients, ENVIVE, an over-the-counter probiotic supplement that is formulated to strengthen and protect the digestive system. In May 2022, Glanbia Nutritionals, an Ireland-based nutrition company, acquired Sterling Technology for an amount of $60 million. Through this acquisition, Glanbia Nutritionals aims to scale and strengthen its bioactive solutions portfolio to cater to the needs of its customers. Sterling Technology is a US-based bioactive solution manufacturing company, which offers product solutions in digestive health, Tegricel, a solution that uses NSAIDs to keep the digestive tract healthy. North America was the largest region in the digestive health supplements market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in digestive health supplements market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the digestive health supplements market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The digestive health supplements market consists of sales of L-glutamine, Slippery elm, Ginger root, and vitamin D. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The digestive health supplements market research report is one of a series of new reports from The Business Research Company that provides digestive health supplements market statistics, including digestive health supplements industry global market size, regional shares, competitors with a digestive health supplements market share, detailed digestive health supplements market segments, market trends and opportunities, and any further data you may need to thrive in the digestive health supplements industry. This digestive health supplements market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Therapeutic proteins refer to pharmaceuticals that are genetically modified versions of human proteins that are found naturally. These powerful, quick-acting medications were developed in a lab for pharmaceutical usage. Therapeutic proteins have altered how diseases are treated since they are very effective in vivo. The main types of products in therapeutic proteins market are insulin, fusion proteins, erythropoietin, interferon, human growth hormone, and follicle-stimulating hormone. Insulin is a peptide hormone produced by beta cells in the pancreatic cells that serves as the individual's primary anabolic hormone. It affects fat, carbohydrate, and protein metabolism by boosting glucose uptake from the blood into the fat, liver, and skeletal muscle cells. The different functions include enzymatic and regulatory activity, special targeting activity, vaccines, and protein diagnostics and are used in various applications such as metabolic disorders, immunologic disorders, haematological disorders, cancer, hormonal disorders, genetic disorders, and others. The global therapeutic proteins market is segmented - 1) By Product Type: Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone 2) By Application: Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications 3) By Function: Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics The global therapeutic proteins market size grew from $112.17 billion in 2022 to $125.74 billion in 2023 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global therapeutic proteins is expected to grow from $200.43 billion in 2027 at a CAGR of 12.4%. The therapeutic proteins market is being driven by technological advancements in protein-based drug development. Therapeutic proteins cannot be synthesised chemically, they need to be produced by genetic engineering and recombinant DNA technology in living cells or organisms. Protein-engineering platform technologies such as glycoengineering, pegylation, Fc-fusion, albumin fusion, and albumin drug conjugation help to increase the production yield, product purity, circulating half-life, targeting, and functionality of therapeutic proteins drugs. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, and recombinant human coagulation factor IX are some therapeutic proteins drugs developed using protein engineering technologies and approved by the FDA in the past five years. Major players in the therapeutic proteins market are Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Pfizer Inc., Johnson & Johnson, and Merck & Co. Inc., Novo Nordisk A/S, and Sanofi. Increasing the number of biosimilar drugs on the global market will slow the growth of the therapeutic proteins market. The patent expiration of therapeutic proteins such as monoclonal antibodies allows biosimilars to enter the market.For instance, in October 2022, Amneal Pharmaceuticals, Inc., a US-based generics and specialty pharmaceutical company, launched ALYMSYS® (bevacizumab-maly) in the United States. These cost-effective treatments, similar to the original biologics, decline the revenue and sales of therapeutic proteins market. Monoclonal antibody drug approvals are increasing in the protein therapeutic segment. Chronic diseases such as cancer and immunological disorders are well treated with monoclonal antibodies. Monoclonal antibodies are a dominant and well-established product class in the protein therapeutic segment, with more safety and immunogenicity than antibodies. By overcoming the problems associated with previous antibody drugs, cell-based expression systems, such as the Chinese hamster ovary (CHO) mammalian cell expression system, have increased the productivity of monoclonal antibodies.In the last five years, the FDA has approved 213 drugs, among which 44 are monoclonal antibodies. For instance, twelve monoclonal antibodies were approved by FDA for the treatment of cancer and immunological disorders. In the United States, therapeutic proteins drug manufacturers file a biologics application (BLA) with the FDA for product approval. The drug that is approved through BLA must be proven to be safe, pure, and potent.FDA consolidated review of most therapeutic proteins in the Center for Drug Evaluation and Research (CDER). In European Union, biologics are regulated by Committee for Medicinal Products for Human Use (CHMP) for marketing authorization. Eli Lilly and Company, a US-based pharmaceutical company, paid $1 billion for Protomer Technologies Inc. in July 2021.Lilly is delighted to add protomer’s breakthrough technology to its diabetes pipeline through this acquisition, since the company’s glucose-sensing insulin program, which is based on its proprietary molecular engineering of protein sensors (MEPS) platform, is exhibiting great potential. Protomer Technologies Inc. is a US-based company that specialises in next-generation protein therapies that can detect molecular activators in the body and are currently being developed. North America was the largest region in the therapeutic proteins market in 2022. The regions covered in the global therapeutic proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the therapeutic proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The therapeutic proteins market consists of sales of antibody-based drugs, FC fusion proteins, and anticoagulants. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The therapeutic proteins market research report is one of a series of new reports from The Business Research Company that provides therapeutic proteins market statistics, including industry global market size, regional shares, competitors with a therapeutic proteins market share, detailed therapeutic proteins market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic proteins industry. The therapeutic proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Nutritional feed additives various types of products used in animal nutrition to improve the nutritional content and quality of feed, or to improve the health and performance of animals. They help improve the nutritional content and quality of feed, resulting in higher productivity and disease prevention. The main additive types of nutritional feed additives are antibiotics, vitamins, antioxidants, amino acids, enzymes, mycotoxin detoxifiers, prebiotics, probiotics, flavours and sweeteners, pigments, binders, and minerals. Antibiotics are medications that aid in the treatment of bacterial illnesses. They accomplish this by either killing the bacteria or preventing them from replicating or reproducing. The nutritional feed additives are available in various forms, such as dry, liquid, and other forms that are used on ruminants, poultry, swine, and aquatic livestock. The additives are distributed through direct, indirect channels, hypermarkets and supermarkets, specialty stores, and online retail channels. The global nutritional feed additives market is segmented - 1) By Distribution Channel: Direct, Indirect, Hypermarket/Supermarket, Specialty Stores, Online Retail 2) By Livestock: Ruminants, Poultry, Swine, Aquatic 3) By Additive Type: Antibiotics, Vitamins, Antioxidants, Amino Acids, Enzymes, Mycotoxin Detoxifiers, Prebiotics, Probiotics, Flavors And Sweeteners, Pigments, Binders, Minerals 4) By Form: Dry, Liquid, Other Forms The global nutritional feed additives market size will grow from $3.89 billion in 2022 to $4.19 billion in 2023 at a compound annual growth rate (CAGR) of 7.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global nutritional feed additives is expected to grow to $5.41 billion in 2027 at a CAGR of 6.6%. The rise in consumption of meat products is one of the driving factors for the nutritional feed additives market. Due to high meat consumption, the concern for high-quality meat is also increasing. Thus, to deliver high-quality meat, add-on nutrition feed additives are fed to the animals so that they have good digestion to build on more muscle and weight. This increases the yield and productivity and, hence, the demand for nutritional feed additives. Currently, meat and poultry consumption in the US is more than 100 billion pounds every year. Major players in the nutritional feed additives market are BASF SE, Cargill, Archer Daniels Midland Company, Evonik Industries AG, Nutreco N.V., Kemin Industries Inc., Adisseo, Alltech, Phibro Animal Health Corporation, and DowDuPont. The stringent regulations act as one of the major restraining factors for the nutritional feed additives market. There are many mandatory documents, required to be approved before approving the nutritional feed, which delays the approval process. Therefore, the product launch and expansion of companies in new regional markets will be delayed. For instance, China's AQSIQ (Administration for Quality Supervision and Inspection and Quarantine) issued 2 reports for the nutrition feed additive companies to get their products registered and approved by the concerned Chinese authorities before selling them in the Chinese market. The report also made it compulsory for all the exporters to have a licence to sell their nutrition feed additive products in the Chinese market, which delays the nutritional feed additives from reaching the stores. Feed additives manufacturers are investing in the R&D of organic feed additives as there is a growing demand for organic and natural feed products in the nutritional feed additives market. When compared to synthetic nutrition feed additives, organic feed additives have fewer side effects and also improve yield. Therefore, poultry farmers are switching to herbal nutrition feed additives. For instance, Agpulse Organics has come up with its herbal animal feed additive 'Govahnika-Biosheera', which is fed to cattle to increase milk productivity while maintaining the health of cattle and quality of milk. In September 2020, Adisseo acquired Framelco G for an undisclosed amount. With this acquisition, the company will enhance the growth of specialties to become the world leader in the field of specialty feed ingredients in animal nutrition. Framelco G is a family-owned multinational company that develops and manufactures feed additives and drinking water solutions for livestock production. North America was the largest region in the nutritional feed additives market in 2022. Asia-Pacific was the second-largest region in the global nutritional feed additives market report. The regions covered in the global nutritional feed additives market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the nutritional feed additives market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The nutritional feed additives market consists of sales of digestibility enhancers, coccidiostats and histomonostats, antimicrobials, and growth hormones. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The nutritional feed additives market research report is one of a series of new reports from The Business Research Company that provides nutritional feed additives market statistics, including nutritional feed additives industry global market size, regional shares, competitors with nutritional feed additives market share, detailed nutritional feed additives market segments, market trends and opportunities, and any further data you may need to thrive in the nutritional feed additives industry. This nutritional feed additives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diagnostic enzymes refer to the enzymes that are employed directly or as part of an assay system to determine the presence or absence of a variety of compounds, and they are used to detect, diagnose, or predict the development of disease conditions. These enzymes are used in diagnosis because of their substrate selectivity and quantified activity when other proteins are present. The main types of products in the diagnostic enzymes market are carbohydrates, polymerases, nucleases, proteases, and others. Any of a class of enzymes (such as amylase) that promotes carbohydrate breakdown or synthesis is referred to as a carbohydrase (such as a disaccharide). The different sources include animals, microorganisms, and plants and are used in biocatalysts, diagnostics, pharmaceuticals, research, and biotechnology. The global diagnostic enzyme market is segmented - 1) By Product Type: Carbohydrases, Polymerases And Nucleases, Protease, and Other Product Types 2) By Source: Animals, Microorganisms, and Plants 3) By Application: Biocatalysts, Diagnostics, Pharmaceuticals, Research, and Biotechnology The global diagnostic enzymes market size grew from $3.8 billion in 2022 to $4.02 billion in 2023 at a compound annual growth rate (CAGR) of 5.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global diagnostic enzymes is expected to grow from $5.1 billion in 2027 at a CAGR of 6.1%. The rise in the geriatric population, which increases the patient pool for the diagnosis of chronic diseases, contributed to the growth of the diagnostic enzymes market. The proportion of people above the age of 65 increased globally, and age-related chronic ailments also increased. For example, the percentage of seniors is expected to grow from 28% in 2019 to 38% by 2050 in Japan. The increase in the ageing population has increased the patient pool of many chronic diseases such as rheumatoid arthritis, hypertension, diabetes, and cancer. People suffering from these diseases are expected to be more vulnerable to chronic diseases, thus significantly influencing market growth during this period. According to the World Population Ageing report, there were 727 million people over the age of 65 in 2020, accounting for 9.3% of the global population, and this figure is expected to rise to around 16.0% by 2050.According to the World Health Organization report for 2021, approximately 10 million cancer-related deaths occurred in 2020. Thus, the rise in the geriatric population increases the number of patients for the diagnosis of chronic diseases, which, in turn, drives the diagnostic enzymes market. Major players in the diagnostic enzymes market are Genzyme, Roche, Codexis, Aldevron, Kaneka Eurogentec, Vigene Biosciences, Amano Enzymes, Advanced Enzymes Technologies, Thermo Fisher Scientific, and EKF Diagnostic. The high sensitivity of enzymes to temperature and pH levels is expected to limit the diagnostic enzymes market. Enzymes need to be stored at optimum temperatures and are generally stored at -20 degrees Celsius. According to the Worthington Biochemical Corporation, variations in the reaction by one or two degrees in temperature may have a change of 10 to 20% in the result. In enzymatic reactions, this is complicated as enzymes are adversely affected by high temperatures, and are expected to be deactivated at even moderate temperatures. Enzymes are affected by changes in pH, as pH is also a factor in the stability of the enzymes. The changes in temperature and pH levels may decrease the efficiency of the diagnostic enzymes, which, in turn, hampers the growth of the diagnostic enzymes market. The use of machine learning and artificial intelligence is gradually gaining popularity in the enzyme diagnostic market. Artificial intelligence (AI) is the simulation of human intelligence in machines and is programmed to display their natural intelligence. Machine learning is a part of AI. Machine learning and AI help companies in the enzyme diagnostic market to conduct a detailed analysis of all relevant data, provide insights into the function of enzymes, and allow physicians to understand the key determinants of the relationship between protein structure, function, and evolution, in terms of the catalysis of the reaction steps of an enzyme. For instance, companies such as BioMarker have invested in AI and machine learning for enzyme diagnostics. In June 2020, Codexis, Inc., a US-based protein engineering company and developer of high-performance enzymes, and Alphazyme LLC., a US-based company in the development and manufacture of nucleic acid metabolising enzymes, announced a co-marketing enzyme supply collaboration agreement for the production and co-marketing of enzymes for life science applications, including diagnostics. This collaboration is expected to leverage the experience and industry knowledge of Alphazyme to accelerate the market introduction of Codexis’ portfolio of high-performing life science and diagnostic enzymes while providing Alphazyme with exclusive manufacturing and co-marketing rights to CodeEvolver-improved enzymes. This partnership will allow both companies to jointly promote and sell these enzymes to innovators in life science and diagnostic markets. North America was the largest region in the enzymes market in 2022. Middle East is expected to be the fastest-growing region in the diagnostic enzyme market report during the forecast period. The regions covered in the diagnostic enzymes analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the diagnostic enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The diagnostic enzymes market consists of sales of acid phosphatase, alanine aminotransferase, cholinesterase, and aspartate aminotransferase. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in the diagnostic enzymes market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The diagnostic enzymes market research report is one of a series of new reports from The Business Research Company that provides diagnostic enzymes market statistics, including global market size, regional shares, competitors with a diagnostic enzymes market share, detailed diagnostic enzymes market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic enzymes industry. The diagnostic enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Protein labelling refers to the process of detecting or purifying the labelled protein and its binding partners by using the proper molecular labels. Most biological research uses one of three basic categories of protein labels: biotin, enzyme conjugates, or fluorescence probes. The main types of products in protein labelling are reagents, proteins, enzymes, probes or tags, and monoclonal antibodies. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different labelling methods include in-vitro labeling, and in-vivo labelling and are used in cell-based assays, fluorescence microscopy, immunological techniques, mass spectrometry, and protein microassays. The global protein labelling market is segmented - 1) By Product: Reagents, Protein, Enzymes, Probes/ Tags, Monoclonal Antibodies 2) By Labeling Method: In-vitro Labeling, In-vivo Labeling 3) By Application: Cell Based-Assay, Fluorescence Microscopy, Immunological Techniques, Mass Spectrometry, Protein Micro Assay The global protein labelling market size will grow from $2.13 billion in 2022 to $2.35 billion in 2023 at a compound annual growth rate (CAGR) of 10.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global protein labelling is expected to grow from $3.49 billion in 2027 at a CAGR of 10.4%. Increased spending on the R&D of proteomics and genomics is driving the growth of the protein labelling reagents market. Proteomics is the study of the overall protein content of a cell, tissue, or organism. Protein labelling methods before separation and analysis are essential during proteomic profiling approaches. For instance, the National Institutes of Health (NIH) of the United States, funded $37 billion for biomedical research. This funding is for life sciences research that supports study at a molecular level for the understanding of fundamental processes by which diseases develop, the identification of biomarkers that signal the presence of disease, or identification of genes or proteins responsible for the disease. The Novo Nordisk Foundation granted a grant of up to $1.5 million to the University of Copenhagen to establish a mass spectrometry facility, which marks a new and exciting step in protein research. Therefore, the increased spending on research and development of proteomics and genomics is driving the market. Major players in the protein labelling market are Thermo Fisher Scientific Inc., Merck KGaA, PerkinElmer, Inc., General Electric Company, F. Hoffmann-La Roche AG, AGILENT TECHNOLOGIES INC., BIO-RAD LABORATORIES, Kirkegaard & Perry Laboratories, LI-COR Inc. and Kaneka Corporation. Drawbacks related to protein labelling techniques are expected to hinder the market. Label-free techniques are preferred over labelled techniques because of the drawbacks associated with them, such as wet-lab complexity and flexibility. While label-free samples can be measured without much preparation, wet lab pre-treatment is required for all labelling techniques. Samples must be labelled with metabolic (e.g. SILAC) or chemical (e.g. iTRAQ or TMT) reagents and the different conditions has to be combined. Therefore, label-free techniques are less prone to wet lab errors than labelling techniques. Label-free approaches have the advantage of being highly adaptable, even after the study has begun. New samples can be included at any time, but labelled approaches require the same number (n) of each condition. New samples may not be included in the study if they cannot be physically mixed and measured with the control. Labeled techniques such as the Super-SILAC approach reduce this problem but must also be carefully planned. These disadvantages are making label-free techniques preferable. Therefore, drawbacks associated with protein labeling techniques are expected to hinder the market. Companies in the protein labelling market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated as well as academic and research institutions in this market by way of partnerships, in or out-licensing deals, this trend has been increasing over recent years. For instance, recombinant protein manufacturer enGenes Biotech GmbH (enGenes) announced a collaboration with ACIB GmbH for protein labeling. In January 2020, Abcam, a UK-based protein research tools producer and seller, announced its decision to acquire Expedeon's Proteomics and Immunology business, which includes Innova and TGR Biosciences. Expedeon technology supports a diverse set of labels, including enzymes, metals, oligos, and fluorescent proteins. Abcam will combine the newly acquired capture and conjugation technologies with its extensive antibody and protein expertise to expand and enhance its portfolio of off-the-shelf, and custom reagents and tools. Expedeon is a Germany-based manufacturer of protein discovery and analysis products used for protein and drug research. North America was the largest region in the protein labeling market in 2022. The regions covered in the global protein labelling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the protein labelling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The protein labeling market includes revenues earned by entities by detecting or purifying the labelled protein and its binding partners. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The protein labelling market research report is one of a series of new reports from The Business Research Company that provides protein labelling market statistics, including the industry's global market size, regional shares, competitors with a protein labelling market share, detailed protein labelling market segments, market trends and opportunities, and any further data you may need to thrive in the protein labelling industry. This protein labelling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Non-alcoholic beer contains 0% to 1.2% of alcohol and it is generally manufactured by removing alcohol from the finished product or by boiling beer to evaporate the alcohol. The main types of non-alcoholic beer are alcohol-free and low alcohol. Low alcohol beers are beer that tastes similar to beer but contains significantly less amount of alcohol. The main types of materials used in producing non-alcoholic beer include malted grains, hops, yeasts, enzymes, and others. The various categories of non-alcoholic beer are plain and flavoured. These types of beer are sold to consumers through store-based and non-store-based sales channels. The global non alcoholic beer market is segmented - 1) By Product: Alcohol free, Low alcohol 2) By Material: Malted Grains, Hops, Yeasts, Enzymes, Other Materials 3) By Category: Plain, Flavored 4) By Distribution Channel: Store-based, Non-Store-based The global non-alcoholic beer market size grew from $18.44 billion in 2022 to $20.16 billion in 2023 at a compound annual growth rate (CAGR) of 9.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The market size of global non-alcoholic beer market is expected to grow to $28.79 billion in 2027 at a CAGR of 9.3%. The growing awareness of the benefits of alcohol-free beverages supported the growth of the non-alcoholic beer market in the historic period. Alcohol-free beer or non-alcoholic beer generally contains negligible or very little alcohol, which usually ranges from 0% to 1.2%. According to an article by Upstream Brewing Company, alcohol-free beer improves cardiovascular health, increases bone mineral density, reduces the risk of osteoporosis, and also stimulates breast milk production. For instance, according to a 2021 survey, 38% of Indians wish to switch from standard strength beer to no or low-alcohol beer. The trend is prevalent among young consumers in the 25 to 34 age group with 41% of young beer consumers willing to switch to no or low-alcohol beers. Therefore, growing awareness of the benefits of alcohol-free beverages supported the growth of the non-alcoholic beer market. Major players in the non-alcoholic beer market areAnheuser-Busch InBev, BERNARD Family Brewery Inc., Big Drop Brewing Co., Carlsberg Breweries Group, Coors Brewing Company, Erdinger Weibbrau, Heineken N.V., Krombacher Brauerei, Moscow Brewing Company, Royal Swinkels Family Brewers, Suntory Holdings Limited, Kirin Brewery Company, and The Bayerische Staatsbrauerei Weihenstephan. Non-alcoholic beer manufacturers are introducing innovative products into the market owing to a significant rise in awareness of health consciousness among consumers. Consumers are more concerned about their health and are accepting paying more for food that is specifically good for their health. There is an increase in demand for low-alcohol and no-alcohol items from people with health illnesses. To capitalize on this, many companies are launching new products into the market to increase their share. For instance, in 2021, UNLTD IPA., an alcohol-free beer manufacturer launched a non-alcoholic beer that has only 13 calories per bottle, is vegan friendly, and is gluten-free. Similarly, Athletic Brewing Company, a non-alcoholic beer producer has launched All Out, an extra dark stout with a full-bodied mouthfeel and toasty finish, accented with coffee and bittersweet chocolate. In August 2022, Finnegans Brew Co., a US-based brewery acquired Hairless Dog Brewing for an undisclosed. This acquisition aligns with an increasing shift away from alcohol usage. Hairless Dog Brewing Co. is a Minneapolis-based non-alcoholic beer company. North America was the largest region in the non-alcoholic beer market in 2022. The regions covered in the non-alcoholic beer market share report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the non-alcoholic beer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The non-alcoholic beer market consists of sales of low alcohol beer and alcohol-free beer. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The non-alcoholic beer market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic beer market statistics, including non-alcoholic beer industry global market size, regional shares, competitors with a non-alcoholic beer market share, detailed non-alcoholic beer market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic beer industry. This non-alcoholic beer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.